Concepedia

Daniela Ribeiro Nebuloni

DR

Statistics

Publications

5

Citations

171

H-Index

5

Active since

2012

Affiliations

Universidade de São Paulo(Current)

Instituto do Câncer do Estado de São Paulo

Hospital Sírio-Libanês

Daniela Ribeiro Nebuloni is an author at Universidade de São Paulo specializing in oncology, medicine, and chemotherapy.

Publications per year

2012–2019

5

Publications

5

Pregabalin for the Prevention of Oxaliplatin-Induced Painful Neuropathy: A Randomized, Double-Blind Trial

Daniel Ciampi de Andrade, Manoel Jacobsen Teixeira, Ricardo Galhardoni et al. · The Oncologist · 2017 · 71 citations · Full text

, , +17

Phase II trial of metformin and paclitaxel for patients with gemcitabine-refractory advanced adenocarcinoma of the pancreas

Maria Ignez Braghiroli, Anezka Ferrari, Tulio Edouardo Pfiffer et al. · ecancermedicalscience · 2015 · 46 citations · Full text

, , +16

Modified FLOX as first-line chemotherapy for metastatic colorectal cancer patients in the public health system in Brazil: Effectiveness and cost-utility analysis

Daniela Ribeiro Nebuloni, Milena Perez Mak, Fabiano Hahn Souza et al. · Molecular and Clinical Oncology · 2012 · 23 citations · Full text

, , +15

Regorafenib in Patients with Antiangiogenic-Naïve and Chemotherapy-Refractory Advanced Colorectal Cancer: Results from a Phase IIb Trial

Rachel P. Riechelmann, Luiz S. Leite, Giovanni M. Bariani et al. · The Oncologist · 2019 · 19 citations · Full text

, , +14

Phase II trial of metformin and paclitaxel for patients with gemcitabine-refractory advanced adenocarcinoma of the pancreas.

Anezka Ferrari, Túlio Pfiffer, Alexandra Khichfy Alex et al. · Journal of Clinical Oncology · 2014 · 12 citations

, , +14

1–5 of 5